ES2131468A1 - Use of melatonin in the treatment of neurodegenerative diseases. - Google Patents

Use of melatonin in the treatment of neurodegenerative diseases.

Info

Publication number
ES2131468A1
ES2131468A1 ES09701212A ES9701212A ES2131468A1 ES 2131468 A1 ES2131468 A1 ES 2131468A1 ES 09701212 A ES09701212 A ES 09701212A ES 9701212 A ES9701212 A ES 9701212A ES 2131468 A1 ES2131468 A1 ES 2131468A1
Authority
ES
Spain
Prior art keywords
melatonin
treatment
neurodegenerative diseases
hormone
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09701212A
Other languages
Spanish (es)
Other versions
ES2131468B1 (en
Inventor
Sanchez Carmen Rodriguez
Barballo Juan Carlos Mayo
Menendez Rosa Maria Sainz
Gonzalez Isaac Antolin
Marban Higinio Uria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Oviedo
Original Assignee
Universidad de Oviedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Oviedo filed Critical Universidad de Oviedo
Priority to ES9701212A priority Critical patent/ES2131468B1/en
Publication of ES2131468A1 publication Critical patent/ES2131468A1/en
Application granted granted Critical
Publication of ES2131468B1 publication Critical patent/ES2131468B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of melatonin in the preparation of useful compositions for preventing and avoiding the progression of symptoms in neurodegenerative diseases. It also relates to the use of this hormone in combination with other antioxidants or with other cellular proliferation inhibitors for the treatment of said conditions. The use of this hormone has the advantages over other drugs used in said treatments that it is an antioxidant and endogenous cellular proliferation inhibitor which does not have side effects, easily crosses the blood-brain barrier and exerts its effects in all the cellular compartments.
ES9701212A 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES. Expired - Fee Related ES2131468B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9701212A ES2131468B1 (en) 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9701212A ES2131468B1 (en) 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Publications (2)

Publication Number Publication Date
ES2131468A1 true ES2131468A1 (en) 1999-07-16
ES2131468B1 ES2131468B1 (en) 2000-04-01

Family

ID=8299558

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9701212A Expired - Fee Related ES2131468B1 (en) 1997-05-29 1997-05-29 USE OF MELATONIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.

Country Status (1)

Country Link
ES (1) ES2131468B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209649A1 (en) * 2002-12-09 2004-06-16 Carlos Arana Molina (Titular Al 25%) Oral hygiene product for human and animal use with a melatonin base as an active product
WO2004058250A1 (en) * 2002-12-31 2004-07-15 Antonio Cutando Soriano Bone regeneration product for human and veterinary use, containing melatonin as active principle

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACUÑA-CASTROVIEJO, D. et al.: "Melatonin is protective against MPTP-induced striatal hippocampal lesions", Life Sciences, (1997), Vol. 60 (2), paginas 23-29 *
ANTON-TAY, F. et al.: "On the effect of melatonin upon human brain. Its possible therapeutic implications", Life Sciences, (1971), Vol. 10, part I, paginas 841-850, paginas 848-849: "discussion". *
GIUSTI, P. et al.: "In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin", J. Pineal Res., (1996), Vol. 20, paginas 226-231 ;rrafo. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209649A1 (en) * 2002-12-09 2004-06-16 Carlos Arana Molina (Titular Al 25%) Oral hygiene product for human and animal use with a melatonin base as an active product
WO2004058250A1 (en) * 2002-12-31 2004-07-15 Antonio Cutando Soriano Bone regeneration product for human and veterinary use, containing melatonin as active principle
ES2213473A1 (en) * 2002-12-31 2004-08-16 Carlos Arana Molina (Titular Al 25%) Bone regeneration product for human and veterinary use, containing melatonin as active principle

Also Published As

Publication number Publication date
ES2131468B1 (en) 2000-04-01

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
AU2002256093A1 (en) Bulking agents as satiety agents
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
UA90668C2 (en) Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
BRPI0207961A8 (en) USE OF EPOTHYLONE AND CAPECITABIN ANALOGS TO MANUFACTURE DRUG TO TREAT SOLID CANCEROUS TUMORS AND KIT COMPRISING THE SAID COMPOUNDS.
SG158733A1 (en) Cell adhesion inhibitors
SE9703693D0 (en) Novel combination
GB0108770D0 (en) Inhibitors
JO2356B1 (en) N-biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives
ZA943744B (en) Therapeutic substituted guanidines
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
ZA951974B (en) Bradykinin antagonist peptides incorporating N-subsituted glycines
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
IL128940A0 (en) C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and pharmaceutical compositions containing them
ATE215953T1 (en) NEW TRICYCLIC COMPOUNDS WITH ICE/CED-3 PROTEASE FAMILY INHIBITING PROPERTIES
DE69934689D1 (en) USE OF PROTEIN KINASE C EPSILON INHIBITORS FOR THE TREATMENT OF PAIN
EP1419129A4 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
HUP9901505A2 (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men
ES2131468A1 (en) Use of melatonin in the treatment of neurodegenerative diseases.
MXPA02010759A (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors.
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
WO2003020304A3 (en) Inflammation modulatory compound comprising an endomorphin
EA200300572A1 (en) COMBINED THERAPY OF ESTROGEN-DEPENDENT DISEASES

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990716

Kind code of ref document: A1

Effective date: 19990716

FD2A Announcement of lapse in spain

Effective date: 20170905